PellePharm Overview

  • Founded

  • 2012

Founded
  • Status

  • Private

  • Employees

  • 8

Employees
  • Latest Deal Type

  • Later Stage VC

  • Latest Deal Amount

  • $70M

  • Investors

  • 8

PellePharm General Information

Description

Developer of skin cancer therapeutics designed to mitigate the tumor burden with basal cell carcinomas. The company's therapeutics include topical hedgehog inhibitor which decreases the number of surgically-eligible basal cell carcinomas in Gorlin Syndrome patients, enabling healthcare providers to treat cancer by potentially reducing invasive and painful surgeries.

Contact Information

Website
www.pellepharm.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Discovery Tools (Healthcare)
Primary Office
  • 101 Mission Street
  • Suite 1950
  • San Francisco, CA 94105
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PellePharm Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 20-Nov-2018 $70M 00000 Completed Clinical Trials - Phase 3
5. Later Stage VC (Series C) 18-Jun-2018 00.00 000.00 00000 Completed Clinical Trials - Phase 3
4. Debt - General 29-Mar-2018 00.00 000.00 Completed Clinical Trials - Phase 3
3. Early Stage VC (Series B2) 31-Jul-2017 0000 000.00 0000 Completed Clinical Trials - Phase 3
2. Early Stage VC (Series B) 23-Jul-2015 $4.55M $7.67M 000.00 Completed Startup
1. Early Stage VC (Series A) 11-May-2015 $3.12M $3.12M 00.00 Completed Startup
To view PellePharm’s complete valuation and funding history, request access »

PellePharm Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 0.000
Series B2 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series B 3,888,889 $0.000100 $0.09 $1.17 $1.17 1x $1.17 8.67%
Series A 3,712,649 $0.000100 $0.84 $0.84 1x $0.84 8.27%
To view PellePharm’s complete cap table history, request access »

PellePharm Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of skin cancer therapeutics designed to mitigate the tumor burden with basal cell carcinomas. The company's th
Drug Discovery
San Francisco, CA
8 As of 2021
00000
0000000000 0 00000

000000

ion ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit
0000 000000000
Branford, CT
00 As of 0000
000.00
0000000000 0 000.00

00000

on ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit i
0000 000000000
San Francisco, CA
0 As of 0000
000.00
000000&0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

PellePharm Competitors (9)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Azitra Venture Capital-Backed Branford, CT 00 000.00 0000000000 0 000.00
00000 00000 Formerly VC-backed San Francisco, CA 0 000.00 000000&0 000.00
0-00000000 Venture Capital-Backed Beerse, Belgium 00 00.000 0000000000 00.000
00000000 000000000 Venture Capital-Backed La Jolla, CA 0 000 00000000000 000
0000000 0000000000 Formerly VC-backed Westlake Village, CA 000 00000 000000000 00000
You’re viewing 5 of 9 competitors. Get the full list »

PellePharm Patents

  • 1

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

PellePharm Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20170231968-A1 Method for relief of and treatment of pruritus Abandoned 11-Feb-2016 00000000000

PellePharm Executive Team (6)

Name Title Board Seat Contact Info
Sanuj Ravindran MD Chief Executive Officer, President & Board Member
Sharon Kokubun Vice President of Finance & Controller
Ervin Epstein MD Co-Founder, Medical Advisor & Board Member
Jean Tang MD Co-Founder, Board Member & Medical Advisor
Philip Beachy Ph.D Co-Founder
You’re viewing 5 of 6 executive team members. Get the full list »

PellePharm Board Members (7)

Name Representing Role Since
Anders Kronborg Self Board Member 000 0000
Eric Aguiar MD Aisling Capital Board Observer 000 0000
Frank McCormick Ph.D Self Board Member 000 0000
Jean Tang MD PellePharm Co-Founder, Board Member & Medical Advisor 000 0000
Katrin Andreasson PellePharm Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

PellePharm Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PellePharm Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
LEO Pharma PE-Backed Company Minority 000 0000 000000 0
Aisling Capital Venture Capital Minority 000 0000 000000 0
EcoR1 Capital Hedge Fund Minority 000 0000 000000 0
Mark De Souza Angel (individual) Minority 000 0000 000000 0
BridgeBio Corporation Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Ready to get started?

Request a free trial